Free Trial
NASDAQ:XLO

Xilio Therapeutics Q4 2023 Earnings Report

Xilio Therapeutics logo
$0.66 +0.01 (+1.09%)
Closing price 08/4/2025 04:00 PM Eastern
Extended Trading
$0.67 +0.01 (+1.81%)
As of 08/4/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xilio Therapeutics EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Xilio Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Xilio Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 1, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Xilio Therapeutics' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 15, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Xilio Therapeutics Earnings Headlines

Xilio Therapeutics (NASDAQ:XLO) Shares Down 2.1% - Time to Sell?
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Xilio Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xilio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xilio Therapeutics and other key companies, straight to your email.

About Xilio Therapeutics

Xilio Therapeutics (NASDAQ:XLO), a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

View Xilio Therapeutics Profile

More Earnings Resources from MarketBeat